Blood biomarkers offer a less invasive and cheaper method for identifying Alzheimer’s disease (AD)-related changes. Already, blood biomarkers for AD are being adopted by clinical practice and their use will only expand in coming years. However, blood biomarkers are susceptible to fluctuations not yet well characterized. Such fluctuations, although rarely observed in current research settings, may influence the biological evaluation of dementia once implemented into routine settings. The study at present aims to identify how blood biomarkers fluctuate over a short period of time in the same individual and assess drivers of these fluctuations.

Draw-10 enrolled approximately 100 participants aged 50-80 years old. Participant population included individuals with normal cognition and MCI based on a screening MoCA of ≥18. Over 9 weeks, participants will provide 10 plasma samples and complete questionnaires at each visit regarding their weekly alcohol use, stress levels, sleep quality and exercise behaviors. pTau-217 assays of different designs (n-terminal, brain-derived, and ratios) will be assessed. Following the conclusion of sample collection, participants will have the option to learn their pTau-217 results from a single validated result via a telehealth visit.